Humana Inc vs Charles Schwab Corporation Common Stock — how do they compare? Humana Inc trades at $437.41 (market cap $47.61B), while Charles Schwab Corporation Common Stock trades at $97 (market cap $165.29B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 3.5× Humana Inc's market cap, and Charles Schwab Corporation Common Stock pays the higher dividend (1.34%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| HUM | SCHW | |
|---|---|---|
Market Cap | $47.61B | $165.29B |
Volume | 1,827,332 | 7,114,246 |
Sector | Health | Financials |
52-Week High | $409.85 | $113.65 |
52-Week Low | $163.67 | $85.35 |
Typical Hold Time | 53 Days | 85 Days |
Enterprise Value | $54.97B | $151.73B |
Dividend Yield | 0.89% | 1.34% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Charles Schwab (SCHW) trades at $96.87, up 0.07% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.62 exceeding expectations of $1.56. Revenue grew to $23.92B in 2025 with 37% profit margin, while analyst consensus remains bullish with a $119.92 price target. Recent developments include dual listing on the Texas Stock Exchange and AI integration partnerships.
SCHW presents a compelling value opportunity with attractive valuation metrics (P/E 17.41) and strong profitability (ROE 22.45%). Near-term risks include technical bearish momentum and market volatility, but long-term growth prospects in the expanding e-brokerage market and operational efficiency gains support upside potential to analyst targets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →